Give Ben Hirschler and Kate Kelland at Reuters credit for a fair presentation this morning of the relative progress made in adult stem cell research compared to that achieved thus far in the embryonic arena. Maybe it was because they were reporting from London, where the constraints of insufferable political advocacy in journalism seem (sad to say) less present than they are in the U.S. Meanwhile, Health Writer Matthew Perrone at the Associated Press couldn't even bring himself to recognize the existence of adult stem cells in his Monday afternoon report, and in the process wrote a flat-out fib about the number of FDA-approved stem cell clinical trials taking place.
The occasion for coverage was Geron Corp.'s decision to halt the first government-approved clinical trial involving embryonic stem cells. What follows after the jump are the first six paragraphs from the Reuters analysis:
On Wednesday, Congressman Henry Waxman cancelled hearings, or what Michelle Malkin referred to as "show trials" in her Friday syndicated column, designed to put the spotlight on companies that dared to do what they legally had to do in response to the passage of ObamaCare: tell the public the estimated impact on their bottom lines relating to a specific tax law chance that was included in the legislation.
Despite the legal requirement, the headline of the Associated Press's coverage on the day of the announcement described the companies' announcements as "gripes." AP Business Writer Matthew Perrone called them "concerns," and acted as if the companies backed down, when the only qualification involved a questionably and largely unrelated item, i.e., what might happen if the law manages to lower overall health care costs.
That journalistically inaccurate narrative gave Waxman an undeserved way out of the heavyhanded mess that he created.
Here are the related paragraphs of Perrone's pathetic piece: